Nautilus Biotechnology, Inc. reported operating expenses of $17.1 million for the second quarter of 2025, an 18% decrease compared to $20.8 million in the corresponding prior year period. The net loss for the quarter was $15.0 million, an improvement from the $18.0 million net loss in the prior year period.
As of June 30, 2025, the company maintained a strong financial position with $179.5 million in cash, cash equivalents, and investments, supporting its extended cash runway through 2027.
The company publicly shared its first scientific manuscript featuring novel data generated using the Nautilus Platform, which introduces and validates the Iterative Mapping method for measuring proteoforms with unprecedented resolution and breadth. This validation demonstrates industry-leading reproducibility with a median CV of 1.5% and a dynamic range exceeding four orders of magnitude.
Nautilus also announced the signing of two collaborations with major research institutes. These partnerships will utilize the Nautilus platform and Tau proteoform assay to study co-incident post-translational modifications on Tau across human tissue and Alzheimer's disease models, aiming to advance understanding of disease-relevant biology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.